Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib as postoperative adjuvant therapy for high-grade soft tissue sarcoma
ChiCTR1900023065Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in soft tissue sarcoma (STS) comparing Anlotinib Group with Placebo Group (2 arms). Primary endpoints: Disease-free survival, 1-year disease-free survival rate and 1 more. Started Mar 2019; status: recruiting.
02
Drugs
anlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR1900023065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023065.